Navigation Links
New clinical trial to test novel approach to treat triple-negative breast cancer
Date:6/2/2011

ert Reece, M.D., Ph.D., M.B.A., vice president of medical affairs at the University of Maryland and dean of the University of Maryland School of Medicine. "This multicenter clinical trial led by Dr. Saranya Chumsri is an excellent example of how our scientists turn discoveries made in the lab into new treatments that may benefit patients."

Entinostat is an oral, selective histone deacetylase (HDAC) inhibitor. This anti-cancer agent is being developed by Syndax Pharmaceuticals, Inc., and is being investigated in other clinical studies for the treatment of advanced estrogen receptor-positive breast cancer, advanced non-small-cell lung cancer, advanced colorectal cancer and Hodgkin's lymphoma.

Triple-negative breast cancer patients in this clinical trial will take entinostat weekly and anastrozole once daily for two to four weeks while they are waiting to have surgery. Researchers will use blood tests and tissue analysis of tumors to evaluate the effectiveness of the combination therapy.

Researchers hope to enroll a total of 41 patients at 20 sites, including the University of Maryland Greenebaum Cancer Center. The centers involved in the study are affiliated with the University of Chicago Phase II study research consortium and the California Cancer Consortium.

Dr. Chumsri says that if the results of this trial are positive, researchers plan to launch a larger study to test the combination therapy on women whose cancer has metastasized to other parts of the body. "These women have limited treatment options. Hopefully, this treatment would give them a longer period in which their cancer is not progressing, with only minimal side effects compared to chemotherapy," she says.


'/>"/>

Contact: Karen E. Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients
2. Clinical study suggests estrogen levels and breast health can be altered
3. Progress toward the clinical application of autologous induced pluripotent stem cells and gene repair therapy for treatment of familial hypercholesterolemia
4. New cancer drug discovered at U-M heads to clinical trials
5. JAMIA: Evaluating clinical information systems, patients who use PHRs, how clinicians use EHRs
6. Preview of oral presentations at the 1st IOF-ESCEO Pre-Clinical Symposium
7. Press registration open for clinical nutrition conference
8. Clinical Benefits of Zimmers DeNovo® NT Natural Tissue Graft in First Surgery Documented in Peer-Reviewed Publication
9. Media alert: ACMG 2011 Clinical Genetics Meeting -- press registration is now open
10. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
11. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New clinical trial to test novel approach to treat triple-negative breast cancer
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
(Date:8/19/2014)... infants born with neonatal abstinence syndrome (NAS) secondary ... time going through withdrawal than others, but the ... and epigenetic (when genes are turned on or ... factors, researchers at Boston University School of Medicine ... first of its kind study to identify some ...
(Date:8/19/2014)... of today,s crocodiles colonised the seas during warm phases ... new Anglo-French study which establishes a link between marine ... a period of more than 140 million years. ... the Universit de Lyon, France and formerly from the ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... Management District (SJRWMD) has contracted with Florida Tech scientists ... regarding the fish larvae and eggs (ichthyoplankton) that inhabit ... a comprehensive SJRWMD effort to address public concern regarding ... St. Johns River. One measure of the ...
... developed the first small molecule that can reversibly activate ... the way for drugs that can treat low blood ... sodium channel (ENaC) controls sodium flow across many tissues ... is vital to maintaining proper salt balance and blood ...
... the fundamental laws of the universe, science is still ... about the meaning of life, the existence of God ... Is that because science is not sufficiently advanced to ... approach to science is incapable of answering humanitys deepest ...
Cached Biology News:Grant to fund answers about St. Johns River 2Finding God with biocomplexity 2Finding God with biocomplexity 3
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/18/2014)... 18, 2014 China is increasingly ... the clinical research industry. Clinicaltrial.gov statistics highlight the ... its aging population; a high increase in infectious ... densely populated pool of patients and a track ... positive points, China also presents challenges for the ...
(Date:8/16/2014)... 2014 Firms in the ... and advisory services to businesses, government bodies and ... services are highly diverse as operators assist a ... from geological and geophysical consulting services to risk ... past five years, the recovery of the Canadian ...
(Date:8/16/2014)... have found a way to make atomic-force microscope probes ... as small as the weight of an individual virus. ... National University (ANU), hinges on using laser beams to ... , "The level of sensitivity achieved after cooling is ... a large virus that is 100 billion times lighter ...
Breaking Biology Technology:TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3Laser makes microscopes way cooler 2
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... from Merz Pharmaceuticals GmbH (Merz) for sales,by ... for the treatment of,moderate-to-severe Alzheimer,s disease during ... exclusive marketing agreement, NTI currently receives,quarterly royalty ...
... evaluation of Botaneco,s technology to add ... functionality to Echium oil ... TSX symbol: SBS, CALGARY, April 30 ... has signed a,feasibility agreement with Croda Enterprise Technology, part of Croda,International Plc, an ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS , ... therapy and oncology, today announced that Prof. Frans ... Men,s Health Institutes,in The Netherlands, won the award ... the 23rd Annual European Association of Urology Meeting, ...
Cached Biology Technology:Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 2Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6
Recombinant Feline IFN-alpha...
Rat monoclonal [HEK/1/85a] to CCR5 ( Abpromise for all tested applications). entrezGeneID: 1234 SwissProtID: P51681...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
...
Biology Products: